In 2016, SPbSRIVS manufactured 20 million doses of influenza vaccines, which is 12 million doses more than last year, with the overall production more than tripled over the past three years. “In 2016, SPbSRIVS manufactured almost half of the total volume of influenza vaccines within the National Vaccination Calendar. In fact, this makes our enterprise one of the leaders among the Russia’s influenza vaccine manufacturers, which imposes a special responsibility on us. Three years ago, such a result was hard to predict. Today we state it,” says Victor Trukhin, Director of SPbSRIVS.
In total, as part of the National Vaccination Calendar, the Ministry of Health of the Russian Federation will purchase about 48 million doses of influenza vaccines in 2016, which will be used for free vaccination of all risk groups. “Influenza vaccines produced at the new, modern facilities of SPbSRIVS meet all international requirements. The production is GMP-certified, which is a guarantee of quality and safety of our vaccines, while original technologies ensure their high efficiency,” adds the Deputy Director of SPbSRIVS Stanislav Petrovsky. The facility for influenza vaccine production of the SPbSRIVS FMBA was modernized and put into operation in the autumn of 2012. The opening was attended by the Minister of Health of the Russian Federation Veronika Skvortsova. “You have developed unique pharmaceutical products that we all may be rightfully proud of: the world’s best drug against highly pathogenic influenza, drugs against seasonal influenza, and various forms of influenza vaccines,” the Russian Minister of Health said then. In 2014, the SPbSRIVS FMBA produced 6.4 million doses, and in 2015, 8 million doses of influenza vaccines.
